SHINGRIX injektiokuiva-aine ja suspensio, suspensiota varten
laakeinfo.fi › MedicineMay 18, 2021 · Shingrix-rokotetta annetaan: 50 vuotta täyttäneille aikuisille; 18 vuotta täyttäneille aikuisille, joilla vyöruusun riski on suurentunut. Shingrix ei sovi vesirokon ehkäisyyn. Mikä vyöruusu on Vyöruusu on rakkulainen ja usein kivulias ihottuma. Sitä esiintyy yleensä yhdellä kehon alueella, ja se voi kestää useita viikkoja.
Administering Herpes Zoster Shingrix Vaccine | CDC
www.cdc.gov › vaccines › vpdShingrix (recombinant zoster vaccine) should be administered to immunocompetent adults aged 50 years and older and adults aged ≥19 years who are or will be immunodeficient or immunosuppressed because of disease or therapy as a two-dose series (0.5 ml each), 2 to 6 months apart (0, 2-6 months). However, for persons who are or will be immunodeficient or immunosuppressed and who would benefit from completing the series in a shorter period, the second dose can be administered 1–2 months ...
Shingles Vaccination: What Everyone Should Know | CDC
www.cdc.gov › vaccines › vpdMay 24, 2022 · CDC recommends that adults 50 years and older get two doses of the shingles vaccine called Shingrix (recombinant zoster vaccine) to prevent shingles and the complications from the disease. Adults 19 years and older who have weakened immune systems because of disease or therapy should also get two doses of Shingrix, as they have a higher risk of getting shingles and related complications.
Shingrix Vaccine FAQs | CDC
www.cdc.gov › vaccines › vpdShingrix is recommended to prevent shingles and related complications in immunocompetent adults 50 years and older, and for adults 19 years and older who are or will be immunocompromised. Make every effort to ensure that two doses are administered within the recommended 2–6 month interval. For immunocompromised adults, a shorter interval of 1–2 months can be followed if the patient would benefit from completing the series in a shorter period.